Kite Pharma
NEWS
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in the life science industry!
This week has marked a number of stories over construction projects and real estate developers focused on the life sciences market. Here’s a look.
Arie Belldegrun, founder and former chair, president and chief executive officer of Kite Pharma, has teamed up with real estate developer Tishman Speyer to launch a biotech-focused real estate company, Breakthrough Properties.
At Kite, Shaw will focus on turning around the company’s flagship CAR-T treatment Yescarta, as well as focus on the development of other cancer-targeting cell therapies.
At the American Society of Clinical Oncology meeting in Chicago, Kite presented updated safety data from the ZUMA-1 trial that introduced a regimen of steroids to CAR-T patients who show early signs of neurologic events reduces the safety concerns associated the CAR-T treatment.
Biocartis Group NV, an innovative molecular diagnostics company, announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company.
On Wednesday, Kite and Gilead announced the 20-acre facility in Fredericksburg that is expected to employ more than 400 people when it becomes operational.
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
JOBS
IN THE PRESS